⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Apeiron Therapeutics (GT Apeiron LLC) and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Apeiron Therapeutics (GT Apeiron LLC)
↗Burlingame, USA / Shanghai, China
Apeiron Therapeutics is a clinical-stage biopharmaceutical company that integrates artificial intelligence with structure-based drug design to develop best-in-class and first-in-class small molecule therapies. The company focuses on biomarker-driven cancer therapeutics to address significant unmet medical needs.
Strategically positioned with operations in the San Francisco Bay Area and Shanghai, Apeiron leverages global talent and technology to streamline the drug development process from target selection to clinical trials. The company is backed by GT Healthcare Capital Partners.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2019
Ownership:private
Status:operating
FUNDING
Stage:Private
Investors:GT Healthcare Capital Partners
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1
Modalities:Small molecule
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:GT Healthcare Capital Partners (Investor/Strategic Partner)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Mingxi Li - CEO
Fred Aswad - Chief Scientific Officer
Xiaohui Gu - Senior Vice President of Chemistry
LINKS
Website:apeiron-bio.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Apeiron Therapeutics (GT Apeiron LLC). The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.